Rivulet Media Inc (fka RIVU)

[Canadian Trader]

Thanks for the insight, and I'd be ecstatic if those numbers were "low" upon approval! As has been mentioned before - given the hassle of setting up an IPO, BMSN must be certain that Regen BioPharma will deliver value. It will be exciting to see if HemaXellerate I is approved for clinical trial; not ony for the upside to stock PPS (both BMSN and now our Regen BioPharma shares), but also for the potential to see this research group treat aplastic anemia in those who suffer from it. It is not too often that you come across an investment opportunity like that.